PDE5 inhibitors

Last updated: November 01, 2022

PDE5 inhibitors

MSNV 699: Pharmacology

MSNV 699: Pharmacology

Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
ACE inhibitors, ARBs and direct renin inhibitors
Miscellaneous lipid-lowering medications
Lipid-lowering medications: Fibrates
Lipid-lowering medications: Statins
Positive inotropic medications
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Adrenergic antagonists: Presynaptic
cGMP mediated smooth muscle vasodilators
Calcium channel blockers
Insulins
Miscellaneous hypoglycemics
Hypoglycemics: Insulin secretagogues
Mineralocorticoids and mineralocorticoid antagonists
Adrenal hormone synthesis inhibitors
Hyperthyroidism medications
Hypothyroidism medications
Gastrointestinal system anatomy and physiology
Anatomy and physiology of the teeth
Enteric nervous system
Gastrointestinal hormones
Hunger and satiety
Chewing and swallowing
Esophageal motility
Gastric motility
Pancreatic secretion
Bile secretion and enterohepatic circulation
Liver anatomy and physiology
Carbohydrates and sugars
Hydration
Proteins
Fats and lipids
Vitamins and minerals
Intestinal fluid balance
Prebiotics and probiotics
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Antiplatelet medications
Anticoagulants: Heparin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Anticoagulants: Warfarin
Acetaminophen (Paracetamol)
Antigout medications
Non-steroidal anti-inflammatory drugs
Osteoporosis medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
General anesthetics
Local anesthetics
Migraine medications
Nonbenzodiazepine anticonvulsants
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Sympathomimetics: Direct agonists
Serotonin and norepinephrine reuptake inhibitors
Selective serotonin reuptake inhibitors
Monoamine oxidase inhibitors
Tricyclic antidepressants
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Psychomotor stimulants
Loop diuretics
Carbonic anhydrase inhibitors
Osmotic diuretics
Potassium sparing diuretics
Thiazide and thiazide-like diuretics
Androgens and antiandrogens
Estrogens and antiestrogens
Progestins and antiprogestins
Uterine stimulants and relaxants
Aromatase inhibitors
PDE5 inhibitors
Antihistamines for allergies
Pulmonary corticosteroids and mast cell inhibitors
Bronchodilators: Leukotriene antagonists and methylxanthines
Bronchodilators: Beta 2-agonists and muscarinic antagonists

Transcript

Watch video only

Phosphodiesterase type 5, or PDE5, inhibitors are a class of medications used to treat erectile dysfunction and pulmonary hypertension.

As their name implies, they inhibit the PDE5 enzyme in endothelial cells, which allows for smooth muscle relaxation and thus, promotes blood vessel dilation.

They include sildenafil, vardenafil, and tadalafil.

Alright, first, let’s focus on the structure of blood vessels.

Blood vessels have three layers, also called “tunics,” or coverings, that surround the vessel lumen, the hollow part of the vessel that contains the blood.

The innermost tunic is the tunica intima, which includes the endothelial cells; the next one is the tunica media, or middle tunic, which is mostly made of smooth muscle cells and sheets of elastin protein; and finally, there’s the tunica externa, or outside tunic, which is made up of loosely woven fibers of collagen.

Moreover, the tunica media can contract, causing vasoconstriction, where the lumen gets a lot smaller; or it can relax, or vasodilate, causing the lumen’s diameter to increase, allowing for more blood flow.

Now, within endothelial cells of the tunica intima, there’s an enzyme called nitric oxide synthase, which uses the amino acid L-arginine and molecular oxygen to synthesize nitric oxide or NO for short.

Once synthesized, nitric oxide diffuses to adjacent smooth muscle cells in the tunica media, where it binds and activates an enzyme called guanylyl cyclase.

This enzyme converts guanosine triphosphate, GTP, into cyclic guanosine monophosphate, cGMP, which is a second messenger that induces relaxation of smooth muscle cells in vessel walls.

Alright, now the cGMP-specific phosphodiesterase type 5, or PDE5, is an enzyme found in various tissues, mainly in the corpus cavernosum of the penis and the retina.

It’s also found in lower concentrations in other tissues including platelets, vascular and visceral smooth muscle, and skeletal muscle.

Recently it’s been discovered to play a role in the cardiovascular system. PDE5 normally breaks down cGMP causing its inactivation.

Okay, now PDE5 inhibitors include sildenafil, vardenafil, and tadalafil.

These medications inhibit the PDE5 enzyme in endothelial cells which normally breaks down cGMP.

Increased cGMP increases the smooth muscle relaxation in response to nitric oxide.

As a result there is an increase in blood flow in the corpus cavernosum of the penis, and a reduction in pulmonary vascular resistance.

Now, PDE5 inhibitors are used in the treatment of erectile dysfunction, which is the inability to develop or maintain an erection due to psychological or organic causes.

It does this by enhancing the erectile response to sexual stimulation.

PDE5 inhibitors also treat pulmonary hypertension, which refers to increased blood pressure in the pulmonary circulation, more specifically, a mean pulmonary arterial pressure that is greater than 25 millimeters of mercury.

Peak plasma concentration of sildenafil occurs approximately 30 minutes to two hours after its given orally and can be delayed by eating.

Key Takeaways

PDE5 (phosphodiesterase type 5) inhibitors are a class of drugs that are used to treat erectile dysfunction and pulmonary hypertension. These drugs work by inhibiting the activity of the enzyme phosphodiesterase type 5 (PDE5), which is responsible for breaking down cyclic guanosine monophosphate (cGMP) in the body. By inhibiting PDE5, these drugs increase the levels of cGMP, which relaxes the smooth muscle tissue in the blood vessels of the penis and lungs, leading to an increase in blood flow. Examples of PDE5 inhibitors include drugs like sildenafil, vardenafil, and tadalafil.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Effect of daily tadalafil on reported outcomes in patients with erectile dysfunction and depressive symptoms" Medicine (2020)
  5. "To evaluate the efficacy and safety of different kinds of PDE5-Is with tamsulosin as a medical therapy for LUTS secondary to benign prostatic hyperplasia" Medicine (2020)
  6. "Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis" International Urology and Nephrology (2017)